Dan J. Broderick

GeneriCo LLC develops and markets generic drugs. The firm also has an embedded drug delivery technology, which used to make generic drugs to the targeted markets. Its products include pipeline and therapeutic areas. The company was founded by Thomas J. Brya, Michael Grimshaw, and Shu Zhu in 2013 and is headquartered in St. Louis, MO.

Apse, Inc. offers technology and strategy services. It develops technology that will allow the cost efficient production of RNA for broad acre topical RNAi uses in agriculture. The company was founded by Juan Arhancet in 2011 and is headquartered in St. Louis, MO.

BacterioScan, Inc. manufacturers and sells in-vitro diagnostic products for lab and clinical care use. Its products include 216Dx UTI system and product pipeline. The firm also offers instrumentation platform that rapidly detects and measures microorganism growth in liquid specimens. The company was founded by Amnon Weichelbaum, Dan Regelman, and Daniel Hofmann in 2004 and is headquartered in St. Louis, MO.

CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University.

GeneriCo LLC develops and markets generic drugs. The firm also has an embedded drug delivery technology, which used to make generic drugs to the targeted markets. Its products include pipeline and therapeutic areas. The company was founded by Thomas J. Brya, Michael Grimshaw, and Shu Zhu in 2013 and is headquartered in St. Louis, MO.

CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University.

Apse, Inc. offers technology and strategy services. It develops technology that will allow the cost efficient production of RNA for broad acre topical RNAi uses in agriculture. The company was founded by Juan Arhancet in 2011 and is headquartered in St. Louis, MO.

Apse, Inc. offers technology and strategy services. It develops technology that will allow the cost efficient production of RNA for broad acre topical RNAi uses in agriculture. The company was founded by Juan Arhancet in 2011 and is headquartered in St. Louis, MO.

GeneriCo LLC develops and markets generic drugs. The firm also has an embedded drug delivery technology, which used to make generic drugs to the targeted markets. Its products include pipeline and therapeutic areas. The company was founded by Thomas J. Brya, Michael Grimshaw, and Shu Zhu in 2013 and is headquartered in St. Louis, MO.

GeneriCo LLC develops and markets generic drugs. The firm also has an embedded drug delivery technology, which used to make generic drugs to the targeted markets. Its products include pipeline and therapeutic areas. The company was founded by Thomas J. Brya, Michael Grimshaw, and Shu Zhu in 2013 and is headquartered in St. Louis, MO.

EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI.

Apse, Inc. offers technology and strategy services. It develops technology that will allow the cost efficient production of RNA for broad acre topical RNAi uses in agriculture. The company was founded by Juan Arhancet in 2011 and is headquartered in St. Louis, MO.

GeneriCo LLC develops and markets generic drugs. The firm also has an embedded drug delivery technology, which used to make generic drugs to the targeted markets. Its products include pipeline and therapeutic areas. The company was founded by Thomas J. Brya, Michael Grimshaw, and Shu Zhu in 2013 and is headquartered in St. Louis, MO.

CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University.

BacterioScan, Inc. manufacturers and sells in-vitro diagnostic products for lab and clinical care use. Its products include 216Dx UTI system and product pipeline. The firm also offers instrumentation platform that rapidly detects and measures microorganism growth in liquid specimens. The company was founded by Amnon Weichelbaum, Dan Regelman, and Daniel Hofmann in 2004 and is headquartered in St. Louis, MO.

EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI.

BacterioScan, Inc. manufacturers and sells in-vitro diagnostic products for lab and clinical care use. Its products include 216Dx UTI system and product pipeline. The firm also offers instrumentation platform that rapidly detects and measures microorganism growth in liquid specimens. The company was founded by Amnon Weichelbaum, Dan Regelman, and Daniel Hofmann in 2004 and is headquartered in St. Louis, MO.

EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI.

CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University.

CS-Keys is the leader in discovery and development of cancer diagnostics based on the science of the DNA Synthesome. As the greatest potential for reducing mortality of cancer lies in the detection of asymptomatic, early stage disease, as well as for residual disease after treatment, the discovery of new markers for this purpose holds significant promise. CS-Keys patented caPCNA antibody may be a powerful ally in helping pathologists achieve this objective. CS-Keys, Inc. is a private, Indianapolis-based biotechnology company focused on the discovery and development of 3rd generation cancer-associated biomarkers using proteomics. These biomarkers may be used to create products to enhance the diagnosis and treatment of patients with cancer. CS-Keys was founded in early 2006 to develop and commercialize products based on the founders research and licensed from Indiana University.

EraGen Biosciences, Inc. is a venture-backed biotechnology company. It designs, develops, manufactures and markets molecular diagnostic testing products and software for the research and clinical testing markets. The firm in-market and pipeline products, based on its novel, patented MultiCode platform chemistry, are the next generation of nucleic acid-based testing for the early detection and monitoring of cancer, genetic and infectious diseases. The company was founded in 1994 and is headquartered in Madison WI.

Apse, Inc. offers technology and strategy services. It develops technology that will allow the cost efficient production of RNA for broad acre topical RNAi uses in agriculture. The company was founded by Juan Arhancet in 2011 and is headquartered in St. Louis, MO.

Apse, Inc. offers technology and strategy services. It develops technology that will allow the cost efficient production of RNA for broad acre topical RNAi uses in agriculture. The company was founded by Juan Arhancet in 2011 and is headquartered in St. Louis, MO.